; Intra Dialytic Hypotension – Pipeline Review, H1 2012
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Intra Dialytic Hypotension – Pipeline Review, H1 2012

VIEWS: 3 PAGES: 33

Intra Dialytic Hypotension – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Intra Dialytic Hypotension - Pipeline Review, H1 2012', provides an overview of the Intra Dialytic Hypotension therapeutic pipeline. This report provides information on the therapeutic development for Intra Dialytic Hypotension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intra Dialytic Hypotension. 'Intra Dialytic Hypotension - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Intra Dialytic Hypotension. - A review of the Intra Dialytic Hypotension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Intra Dialytic Hypotension pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Intra Dialytic Hypotension.

More Info
  • pg 1
									Intra Dialytic Hypotension – Pipeline Review, H1 2012




  Intra Dialytic Hypotension – Pipeline Review, H1 2012
                                                                                          Reference Code: GMDHC1699IDB
                                                                                            Publication Date: January 2012




Intra Dialytic Hypotension – Pipeline Review, H1 2012                                      GMDHC1699IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Intra Dialytic Hypotension – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 3
    List of Figures ................................................................................................................................................................................ 3
Introduction......................................................................................................................................................................................... 4
    Global Markets Direct Report Coverage ........................................................................................................................................ 4
Intra Dialytic Hypotension Overview ................................................................................................................................................... 5
Therapeutics Development................................................................................................................................................................. 6
    An Overview of Pipeline Products for Intra Dialytic Hypotension ................................................................................................... 6
Intra Dialytic Hypotension Therapeutics under Development by Companies ..................................................................................... 8
Mid Clinical Stage Products................................................................................................................................................................ 9
    Comparative Analysis .................................................................................................................................................................... 9
Early Clinical Stage Products ........................................................................................................................................................... 10
    Comparative Analysis .................................................................................................................................................................. 10
Intra Dialytic Hypotension Therapeutics – Products under Development by Companies ................................................................. 11
Companies Involved in Intra Dialytic Hypotension Therapeutics Development ................................................................................ 12
    Medinox, Inc. ............................................................................................................................................................................... 12
    Chelsea Therapeutics, Inc. .......................................................................................................................................................... 13
Intra Dialytic Hypotension – Therapeutics Assessment .................................................................................................................... 14
    Assessment by Monotherapy Products ....................................................................................................................................... 14
    Assessment by Route of Administration ...................................................................................................................................... 15
    Assessment by Molecule Type .................................................................................................................................................... 18
Drug Profiles..................................................................................................................................................................................... 21
    Northera - Drug Profile ................................................................................................................................................................ 21
         Product Description................................................................................................................................................................. 21
         Mechanism of Action ............................................................................................................................................................... 21
         R&D Progress ......................................................................................................................................................................... 21
    Norathiol - Drug Profile ................................................................................................................................................................ 24
         Product Description................................................................................................................................................................. 24
         Mechanism of Action ............................................................................................................................................................... 24
         R&D Progress ......................................................................................................................................................................... 24
Intra Dialytic Hypotension Therapeutics – Drug Profile Updates ...................................................................................................... 25
Intra Dialytic Hypotension Therapeutics - Dormant Products ........................................................................................................... 29
Intra Dialytic Hypotension – Product Development Milestones ........................................................................................................ 30
    Featured News & Press Releases ............................................................................................................................................... 30
         Nov 19, 2008: Chelsea Therapeutics Completes Enrollment In Phase II Trial Of Droxidopa In Intradialytic Hypotension ...... 30
         Jan 07, 2007: Chelsea Therapeutics Initiates Phase II Study Of Droxidopa In Intradialytic Hypotension .......................
								
To top